In my view, this was a clear case of $INTC (-12,36 %) . Around 90% in 12 hours was ok. It will be similar on Wednesday at $ASML (-0,78 %) and on 04.02. at $NOVO B (-0,19 %) . However, go short on both beforehand, as the figures do not come after the close of trading. With $ASML (-0,78 %) I am already in.

happy wife, happy life. Just under 33% profit.

There are currently rumors that a new partnership could emerge following the dissolution of the partnership in summer 2025. This could involve $HIMS (-3,47 %) Wegovy and oral medication... from $NOVO B (-0,19 %) directly without generics.

This would of course be a very bullish signal.

Brief evidence why this could happen: Novo Nordisk has filed 140 lawsuits against compounders but none against Hims, which are extremely compounders (still...)

So I could well imagine this happening.

Nevertheless, I would adjust GLP-1 from the balance sheet/income statement without considering this business. For me, that would merely be a bonus.

The momentum is currently catastrophic and the CEO must finally come forward, we are waiting for Q4!

Nevertheless, as you know, I have been very bullish for a long time and have about 20% of my portfolio in Hims (at the ATH even with 30%),

Don't forget, as Bezos once said: The stock is not the business, P/E ratio of 3, growth of 50%, clean balance sheet that is constantly improving...

I remain invested and continue to watch Hims!

$NOVO B (-0,19 %) and the battle for the 200-day line!

The Novo Nordisk share is currently stuck at the 200-day line after its strong rally from its low of 266.90 Danish kroner at the end of November. Recently, some analysts have also been rather cautious, which means that momentum is currently lacking. Meanwhile, investors should keep an eye on an important date.

Several analyst firms remain cautiously positioned on Novo Nordisk ahead of the fourth quarter figures, which are to be presented on February 4. UBS is sticking to its neutral assessment and sees the fair value of the share at 390 Danish kroner. The group's outlook for 2026 is expected to be rather defensive. The analysts believe that the oral version of the weight loss drug Wegovy will remain decisive, particularly with regard to its earning power.

Barclays also remains cautious and continues to rate the share at "Equal Weight". The target price is 360 crowns. Initial market signals following the start of sales of the tablet form of Wegovy at the beginning of January are highlighted as encouraging.

Jefferies is much more skeptical. The analyst firm confirms its sell recommendation with a target price of 270 crowns. In the short term, weekly sales data from Wegovy in particular will influence the share price. However, despite high demand at the beginning of the year, the analysts do not expect any noticeable positive effects on business development - neither in 2025 nor in 2026.

I feel very comfortable with my short. As long as we don't close above 400DKK, everything is in the green.

I have disposed of some shares in my portfolio and some new ones have made it into the portfolio

Sold:

$ASML (-0,78 %) (+77.44 %) went well for me, I will possibly get back in if there is a strong setback

$PUM (-14,16 %) (+5.76) I don't see much potential at the moment

$NOVO B (-0,19 %) (2.53 %) I am waiting for a setback and will get back in lower

new additions to the portfolio today:

$ONDS (-4,64 %)

$NOW (+3,06 %)

$GIS (-0,85 %)

added to the portfolio last week:

$ASPI (+2,54 %)

$9880 (+0,16 %)

The entry price doesn't quite fit...

I am taking this trade for two reasons

1. as a consolation in case the whole situation between Denmark/Europe versus the USA escalates.

2. and as a trade that the figures that will be presented soon will miss forecasts, at least in terms of profit...

Only accounts for 1.2% of my portfolio, so really only a small position of around €130...

LG small investor 👋

$NOVO B (-0,19 %)

Oh well, there has to be a bit of excitement and fun. Therefore, as announced on the WE, short on $NOVO B (-0,19 %)